Purpose:; Lobular carcinoma; in situ; (LCIS) is a preinvasive lesion of the breast. We sought to define its genomic landscape, whether intralesion genetic heterogeneity is present in LCIS, and the clonal relatedness between LCIS and invasive breast cancers.; Experimental Design:; We reanalyzed whole-exome sequencing (WES) data and performed a targeted amplicon sequencing validation of mutations identified in 43 LCIS and 27 synchronous more clinically advanced lesions from 24 patients [9 ductal carcinomas; in situ; (DCIS), 13 invasive lobular carcinomas (ILC), and 5 invasive ductal carcinomas (IDC)]. Somatic genetic alterations, mutational signatures, clonal composition, and phylogenetic trees were defined using validated computational metho...
BACKGROUND: Intratumoral heterogeneity may help drive resistance to targeted therapies in cancer. In...
Invasive lobular breast cancer (ILC) accounts for 10-15% of all invasive breast carcinomas. It is ge...
Invasive lobular carcinoma (ILC) is the second most frequently occurring histological breast cancer ...
BACKGROUND: Lobular carcinoma in situ (LCIS) is a non-invasive breast lesion that is typically found...
INTRODUCTION: Lobular carcinoma in situ (LCIS) has been accepted as a marker of risk for the develop...
Lobular carcinoma in situ (LCIS) and atypical lobular hyperplasia (ALH) of the breast are cytologica...
Introduction: Lobular carcinoma in situ (LCIS) has been accepted as a marker of risk for the develop...
Lobular carcinoma in situ (LCIS) is considered to be a risk factor for the development of invasive b...
PURPOSE: Invasive lobular breast cancer (ILBC) is the second most common histologic subtype after in...
Invasive lobular carcinoma (ILC) accounts for up to 15% of all invasive breast cancers. We have long...
PURPOSE: Invasive lobular breast cancer (ILBC) is the second most common histologic subtype after in...
Several models have been described as potential mechanisms for the progression of ductal carcinoma i...
PURPOSE: Invasive lobular carcinoma (ILC) represents the second most common histologic breast cancer...
BACKGROUND:Ductal carcinoma in situ (DCIS) of the breast is heterogeneous in terms of the risk of pr...
Invasive lobular carcinoma (ILC) is the second most prevalent histologic subtype of invasive breast ...
BACKGROUND: Intratumoral heterogeneity may help drive resistance to targeted therapies in cancer. In...
Invasive lobular breast cancer (ILC) accounts for 10-15% of all invasive breast carcinomas. It is ge...
Invasive lobular carcinoma (ILC) is the second most frequently occurring histological breast cancer ...
BACKGROUND: Lobular carcinoma in situ (LCIS) is a non-invasive breast lesion that is typically found...
INTRODUCTION: Lobular carcinoma in situ (LCIS) has been accepted as a marker of risk for the develop...
Lobular carcinoma in situ (LCIS) and atypical lobular hyperplasia (ALH) of the breast are cytologica...
Introduction: Lobular carcinoma in situ (LCIS) has been accepted as a marker of risk for the develop...
Lobular carcinoma in situ (LCIS) is considered to be a risk factor for the development of invasive b...
PURPOSE: Invasive lobular breast cancer (ILBC) is the second most common histologic subtype after in...
Invasive lobular carcinoma (ILC) accounts for up to 15% of all invasive breast cancers. We have long...
PURPOSE: Invasive lobular breast cancer (ILBC) is the second most common histologic subtype after in...
Several models have been described as potential mechanisms for the progression of ductal carcinoma i...
PURPOSE: Invasive lobular carcinoma (ILC) represents the second most common histologic breast cancer...
BACKGROUND:Ductal carcinoma in situ (DCIS) of the breast is heterogeneous in terms of the risk of pr...
Invasive lobular carcinoma (ILC) is the second most prevalent histologic subtype of invasive breast ...
BACKGROUND: Intratumoral heterogeneity may help drive resistance to targeted therapies in cancer. In...
Invasive lobular breast cancer (ILC) accounts for 10-15% of all invasive breast carcinomas. It is ge...
Invasive lobular carcinoma (ILC) is the second most frequently occurring histological breast cancer ...